ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

AACI to coordinate clinical trials project.

October 17, 2003

NCI Intramural Budget: Well-Funded Labs, High Costs, Or Deceiving Appearances?

April 21, 1995

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

January 28, 2005

In Brief : Patricia LoRusso Named Associate Director Of Innovative Medicine at Yale Cancer Center

June 20, 2014

Study Supports Immediate Breast Reconstruction

September 24, 2004

Pennsylvania Cancer Center Gets $100 Million; Watson, Weinberg, Win National Science Medals

December 19, 1997